Atorlip 20: Effective LDL Cholesterol Management for Cardiovascular Health
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.12 | $63.64 (0%) | 🛒 Add to cart |
| 60 | $1.91 | $127.28 $114.38 (10%) | 🛒 Add to cart |
| 90 | $1.83 | $190.92 $165.12 (14%) | 🛒 Add to cart |
| 120 | $1.78 | $254.56 $214.14 (16%) | 🛒 Add to cart |
| 180 | $1.75 | $381.84 $315.62 (17%) | 🛒 Add to cart |
| 270 | $1.73
Best per pill | $572.76 $466.12 (19%) | 🛒 Add to cart |
Atorlip 20 contains atorvastatin calcium, a potent lipid-lowering agent belonging to the statin class. This medication is specifically formulated to reduce elevated levels of low-density lipoprotein (LDL) cholesterol, total cholesterol, and triglycerides, while increasing high-density lipoprotein (HDL) cholesterol in adult patients. It is indicated as an adjunct to diet and lifestyle modifications for the primary and secondary prevention of cardiovascular events. Clinical evidence supports its efficacy in slowing the progression of atherosclerosis and reducing the risk of myocardial infarction and stroke in at-risk populations.
Features
- Active ingredient: Atorvastatin calcium 20 mg
- Pharmaceutical form: Film-coated tablets
- Mechanism: Competitive inhibitor of HMG-CoA reductase
- Bioavailability: Approximately 14%
- Protein binding: ≥98%
- Metabolism: Hepatic via CYP3A4
- Elimination half-life: 14 hours
- Excretion: Primarily biliary
Benefits
- Significantly reduces LDL cholesterol levels by 40-50% at this dosage
- Lowers triglyceride levels and modestly increases HDL cholesterol
- Demonstrates proven cardiovascular risk reduction in clinical trials
- Slows progression of coronary atherosclerosis
- Reduces incidence of ischemic stroke in appropriate patient populations
- Provides 24-hour lipid-lowering effect with once-daily dosing
Common use
Atorlip 20 is primarily prescribed for patients with primary hypercholesterolemia (including heterozygous familial hypercholesterolemia) and mixed dyslipidemia. It is utilized in both primary prevention for patients with multiple risk factors but no established cardiovascular disease, and secondary prevention for those with existing coronary heart disease. The medication is particularly effective in diabetic patients with dyslipidemia and is often incorporated into comprehensive cardiovascular risk management protocols. Clinical guidelines recommend its use following inadequate response to dietary changes and other non-pharmacological interventions.
Dosage and direction
The recommended starting dose is 10 mg or 20 mg once daily, with Atorlip 20 representing a moderate-intensity statin therapy. Dosage may be adjusted based on lipid response and tolerability, with a maximum recommended dose of 80 mg daily. Administration should occur at any time of day, with or without food, though consistency in timing is advised. Dose adjustments are necessary in patients taking concomitant CYP3A4 inhibitors and in those with renal impairment. Liver function tests should be performed before initiation and periodically during treatment.
Precautions
Liver function monitoring is essential before starting therapy and periodically thereafter. Patients should report unexplained muscle pain, tenderness, or weakness promptly. Caution is advised in patients with history of liver disease, excessive alcohol consumption, or renal impairment. The medication may increase HbA1c and fasting serum glucose levels. Ophthalmological examinations are recommended if visual changes occur. Patients should be advised that grapefruit juice may increase atorvastatin concentrations and should be avoided.
Contraindications
Active liver disease or unexplained persistent elevations of serum transaminases. Hypersensitivity to any component of this medication. Pregnancy and breastfeeding are absolute contraindications due to potential fetal harm and excretion in breast milk. Concomitant use with strong CYP3A4 inhibitors such as itraconazole, ketoconazole, and certain HIV protease inhibitors is contraindicated.
Possible side effects
Common adverse reactions include headache, myalgia, arthralgia, diarrhea, nausea, and elevated liver enzymes. Less frequent side effects include insomnia, nightmares, and dizziness. Serious but rare adverse effects include rhabdomyolysis with renal dysfunction, hepatotoxicity, and immune-mediated necrotizing myopathy. Pancreatitis and peripheral neuropathy have been reported in post-marketing surveillance. Most side effects are dose-dependent and reversible upon discontinuation.
Drug interaction
Significant interactions occur with strong CYP3A4 inhibitors (clarithromycin, HIV protease inhibitors), which increase atorvastatin exposure. Concurrent use with gemfibrozil increases risk of myopathy. Cyclosporine significantly increases atorvastatin concentration. Warfarin therapy requires enhanced INR monitoring. Oral contraceptives containing ethinyl estradiol and norgestrel show increased AUC. Digoxin levels may be slightly increased. Antacids decrease atorvastatin absorption when taken simultaneously.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped and the regular dosing schedule resumed. Doubling the dose to make up for a missed dose is not recommended. Consistent daily administration is important for maintaining stable lipid-lowering effects.
Overdose
There is no specific antidote for atorvastatin overdose. Supportive measures should be implemented with symptomatic treatment. Gastric lavage may be considered if ingestion occurred recently. Liver function and CPK levels should be monitored closely. Hemodialysis is not expected to significantly enhance elimination due to extensive protein binding. Cases of overdose have generally been followed by complete recovery without sequelae.
Storage
Store at room temperature between 15-30°C (59-86°F) in the original container. Protect from light and moisture. Keep tightly closed and out of reach of children. Do not use if the blister pack is damaged or tablets show signs of deterioration. Proper disposal of unused medication should follow local regulations for pharmaceutical waste.
Disclaimer
This information is provided for educational purposes only and does not constitute medical advice. Atorlip 20 is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and appropriate monitoring is essential. Patients should not adjust dosage or discontinue treatment without consulting their physician. The full prescribing information should be consulted before initiating therapy.
Reviews
Clinical studies demonstrate that Atorlip 20 produces significant LDL-C reductions of 43-50% from baseline in most patients. The Scandinavian Simvastatin Survival Study (4S) and other major trials have established the cardiovascular benefits of statin therapy. Real-world evidence supports good tolerability with long-term use, though individual experiences may vary. Patient satisfaction surveys indicate high adherence rates when combined with proper education about benefits and side effect management.